Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies

Drug Category: Array
Conference Category: Array
Lead Author: Cheah C, et al.
Published Date: 11/06/2021
Download Link: /wp-content/uploads/2021/06/Dr.-Chan-Cheah-EHA2021-TG-1701-Poster-FINAL.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top